Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Colorcon
Medtronic
Baxter
AstraZeneca

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,572,854

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,572,854
Title:Treatment of protein degradation disorders
Abstract: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
Inventor(s): Anderson; Kenneth C. (Wellesley, MA), Bradner; James E. (Weston, MA), Greenberg; Edward Franklin (Cleveland, OH), Hideshima; Teru (Brookline, MA), Kwiatkowski; Nicholas Paul (Auburn, MA), Mazitschek; Ralph (Belmont, MA), Schreiber; Stuart L. (Boston, MA), Shaw; Jared (Davis, CA), Haggarty; Stephen J. (Gloucester, MA)
Assignee: President and Fellows of Harvard College (Cambridge, MA) Dana-Farber Cancer Institute, Inc. (Boston, MA)
Application Number:14/679,800
Patent Claims:1. A method of treating a subject suffering from a solid tumor comprising administering to the subject a therapeutically effective amount of a proteasome inhibitor and an aggresome inhibitor, wherein the aggresome inhibitor selectively inhibits HDAC6.

2. The method of claim 1, wherein the solid tumor is a breast, lung, liver, colon or prostate solid tumor.

3. The method of claim 1, wherein the proteasome inhibitor is selected from the group consisting of bortezomib, MG132, sapojargon, and NPI-0052.

4. The method of claim 1, wherein the aggresome inhibitor is of the formula: ##STR00074## or a pharmaceutically acceptable salt thereof, wherein: R.sub.1 is cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; --OR.sub.A; --C(.dbd.O)R.sub.A; --CO.sub.2R.sub.A; --SR.sub.A; --SOR.sub.A; --SO.sub.2R.sub.A; --N(R.sub.A).sub.2; --NHC(O)R.sub.A; or --C(R.sub.A).sub.3; wherein each occurrence of R.sub.B is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety; R.sub.2 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstitued aryl; substituted or unsubstituted heteroaryl; --OR.sub.B; --C(.dbd.O)R.sub.B; --CO.sub.2R.sub.B; --CN; --SCN; --SR.sub.B; --SOR.sub.B; --SO.sub.2R.sub.B; --NO.sub.2; --N(R.sub.B).sub.2; --NHC(O)R.sub.B; or --C(R.sub.B).sub.3; wherein each occurrence of R.sub.B is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety; and R.sub.3 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstitued aryl; substituted or unsubstituted heteroaryl; --OR.sub.C; --C(.dbd.O)R.sub.C; --CO.sub.2R.sub.C; --CN; --SCN; --SR.sub.C; --SOR.sub.C; --SO.sub.2R.sub.C; --NO.sub.2; --N(R.sub.C).sub.2; --NHC(O)R.sub.C; or --C(R.sub.C).sub.3; wherein each occurrence of R.sub.C is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety.

5. The method of claim 1, wherein the aggresome inhibitor is of the formula: ##STR00075## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is hydrogen, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; n is 1-5; R.sup.2 is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; X is --O--, --C(R.sup.2A).sub.2--, --S--, or --NR.sup.2A--, wherein R.sup.2A is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; or wherein two or more occurrences of R.sup.2 and R.sup.2A, taken together, form an alicyclic or heterocyclic moiety, or an aryl or heteroaryl moiety; R.sup.3 is an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; and Y is hydrogen or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety.

6. The method of claim 1, wherein the aggresome inhibitor is selected from the group consisting of: ##STR00076## ##STR00077## and pharmaceutically acceptable salts thereof.

7. The method of claim 1, wherein the aggresome inhibitor is the following: ##STR00078## or a pharmaceutically acceptable salt thereof.

8. The method of claim 1, wherein the aggresome inhibitor is of the following formula: ##STR00079## or a pharmaceutically acceptable salt thereof, wherein: each X is independently O, S, CH.sub.2, or NR.sub.3; Y is O, S, CH.sub.2, or NR.sub.4; Ar.sub.1 and Ar.sub.2 are each independently an aryl group; R.sub.1 is a lower alkyl group or an aryl group; R.sub.2 is hydrogen, a lower alkyl group or an aryl group; and R.sub.3 is hydrogen, a lower alkyl group, an aryl group, an alkylcarbonyl, an alkoxycarbonyl group, or an aminocarbonyl group.

9. The method of claim 8, wherein: X is for both occurrences O; Y is S; Ar.sub.1 is phenyl or substituted phenyl; Ar.sub.2 is heteroaryl; R.sub.1 is phenyl or substituted phenyl; and R.sub.2 is hydrogen.

10. The method of claim 1, wherein the aggresome inhibitor inhibits the C-terminal aceylation activity of HDAC6, thereby inhibiting aggresome mediated protein degradation.

11. The method of claim 1, wherein the aggresome inhibitor is dyenin.

12. The method of claim 1, further comprising obtaining a biological sample from a subject.

13. The method of claim 1, further comprising administering a therapeutically effective amount of one or more additional protein degradation inhibitors to the subject.

14. The method of claim 13, wherein at least one of the additional protein degradation inhibitors is an aggresome inhibitor.

15. The method of claim 13, wherein at least one of the additional protein degradation inhibitors is a proteasome inhibitor.

16. The method of claim 1, further comprising monitoring the treatment or progress of the subject.

17. The method of claim 1 further comprising co-administering one or more of a chemotherapeutic agent, radiation agent, hormonal agent, biological agent, or an anti-nflammatory agent to the subject.

18. The method of claim 17, wherein the chemotherapeutic agent is tamoxifen, trastuzamab, raloxifene, doxorubicin, fluorouracil/5-fu, pamidronate disodium, anastrozole, exemestane, cyclophosphamide, epirubicin, letrozole, toremifene, fulvestrant, fluoxymesterone, trastuzumab, methotrexate, megastrol acetate, docetaxel, paclitaxel, testolactone, aziridine, vinblastine, capecitabine, goselerin acetate, zoledronic acid, taxol, or vincristine.

19. The method of claim 8, wherein: X is for both occurrences O; Y is S; Ar.sub.1 is phenyl or substituted phenyl; Ar.sub.2 is optionally substituted oxazolyl; R.sub.1 is 4-aminosubstituted phenyl; and R.sub.2 is hydrogen.

20. The method of claim 1, wherein the subject is a human.

Details for Patent 9,572,854

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Sign up for a Free Trial 2025-03-22
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Sign up for a Free Trial 2025-03-22
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 2019-02-28 ⤷  Sign up for a Free Trial 2025-03-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Dow
Moodys
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.